Thyroid cancer is a type of cancer which takes place when abnormal cells starts to grow in the thyroid gland which are responsible for excretion of thyroid hormone. The diagnostic procedure is performed including blood test, imaging and biopsy to identify thyroid cancer depending on two form of cancer, i.e. papillary and follicular thyroid cancer. These thyroid cancer account for more than 90% of all thyroid cancer as they tend to grow slow. The cause of thyroid cancer is unclear, but risk factors for certain have been recognized, including family history of goiter, high radiation exposure and some hereditary syndromes. The National Cancer Institute recommends that one who received radiation to head or neck in childhood be examined to detect potential cancer. Thus, rising awareness on precursory diagnosis and treatment is the vital factor escalating the market growth. Moreover, the research and development are being undertaken for the development of precise diagnostic system to enhance diagnosis procedure. It is estimated that the incidence of thyroid cancer is 1% – 5% in females and 2% in males, and is the 7th most common cancer in females and the 14th most common cancer in males. The most recent predictions from the American Cancer Society for thyroid cancer in the United States for 2020 are nearly 52,890 new cases of thyroid cancer (12,720 in men and 40,170 in women)
The global thyroid cancer diagnosis market is driven by the increasing incidence of thyroid cancer and early diagnosis with treatment drive the market growth. Beside advanced diagnostic tools for analysis is another factor driving growth. The increase in funding for research and development and introduction of a new advanced testing device is bound to enhance the global diagnosis of thyroid cancer. However late diagnosis and lack of concern are the major factor that stop the growth of market. For instance in August 2019, New Diagnostic Tool for Thyroid Cancer introduced Hyperspectral Raman microscopy has been developed into a highly sensitive and highly precise objective method in the analysis of single cell aspiration (FNA) biopsies to enable minimally invasive diagnosis of "indeterminate" thyroid nodules and similarly challenging presentations, according to the results of a study published in Biomedical Optics Express.
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the thyroid cancer diagnosis market. In addition, complete analysis of changes on the thyroid cancer diagnosis market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID 19 impact on the thyroid cancer diagnosis market is estimated to have a positive impact for the market growth. As the number of thyroid disorder and cancer patient are increasing the demand for the diagnosis technique is increasing in the hospital , clinics , diagnostic center and research institute which is allowing companies to make major production of diagnostic tool including imaging technique and biopsy. As, these techniques are commonly used to diagnose a particular form of thyroid cancer disease.
The global thyroid cancer diagnosis market is segmented by type, by technique, End user and geography.
The diagnosis of thyroid cancer is made according to specific type of carcinoma such as papillary thyroid carcinoma and follicular thyroid carcinoma.
Papillary thyroid cancer (PTC) is the most prevalent type of malignancy among all thyroid cancers. It is also one of the few cancers that has a steadily growing incidence. This condition records to have a highest cure rate among the cancer type. Follicular thyroid cancer is the second most common cause of thyroid cancer, and it accounts for 4% to 39% of all thyroid cancers. Follicular thyroid cancer is more common in older females, with a female to male ratio of 3 to 1, and an average age of 60. Other forms of the condition include Hurthle cell carcinoma, medullary thyroid carcinoma, and anaplastic carcinoma.
To identify the type of carcinoma present several techniques are used for diagnosis like blood test , imaging including ultrasound, radio iodine scan , computed tomography scan, MRI scan, PET scan and biopsy.
Blood tests is used to determine if the thyroid is working properly, or excessively. The imaging segment holds the largest market share. The primary objective of disease diagnosis and cancer staging maintains the imaging examination. CT and MRI scans are commonly recommended for diagnosis by practitioners. Other imaging such as Chest X-Ray, PET scan and radio iodine scan are used for identifying. In order to detect a thyroid cancer lump, a gland biopsy is performed. Biopsy, a simple procedure involves extracting a small piece of thyroid tissue and then testing for cancerous growth.
The majority of people with thyroid cancer are diagnosed in the Hospital Clinics, Cancer Diagnostic Centers and Research Institute.
Hospital laboratories held the largest share, as this section attributes to rising patient inflows for cancer diagnosis in hospitals and growing consumer awareness of thyroid cancer. As hospital have their separate laboratories for diagnosis and treatment depending on cancer type. Cancer diagnostic centers are specifically used to diagnose by using multiple methods such as imaging, which can be helpful to doctors for further therapy.
Geographically the global thyroid cancer diagnosis market is having its major wages in North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA)
North America accounted for a significant market share in 2019, due to the excellent commercial success including its diagnosis of thyroid cancer. The rise in healthcare expenditure and core manufacturing are contributing to the growth of the market in the region. Asia Pacific is projected to rise at the highest pace due to an increase in the incidence and recognition of thyroid cancer.
The global thyroid cancer diagnosis key players are Merck KGaA, Abbott, F.Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Siemens Healthcare GmbH,Bio-Rad Laboratories, Inc., General Electric, Koninklijke Philips N.V., Toshiba Corporation, Agilent Technologies, Inc.,Illumina, Inc., GE Healthcare, Hologic, Inc., Medlife International Private Limited, Randox Laboratories Ltd , Tosoh India Pvt. Ltd., Quidel Corporation, American Cancer Society, Inc
March 2019: As part of a strategic technology partnership with Siemens Healthineers, the Braunschweig Municipal Hospital has introduced new molecular diagnostic technologies that will recognize genetic changes in cancer cells. Pathologists can indeed effectively detect patients eligible for personalized care based on the genetic make-up of their tumors. The method has been developed by Neo New Oncology, a subsidiary of Siemens Healthineers.
The report analyses the global Thyroid Cancer Diagnosis market based on by type, technique, End user and geography. The Thyroid Cancer Diagnosis for carcinoma are of two type papillary thyroid carcinoma and follicular thyroid carcinoma. The technique available in market are blood test, imaging and biopsy.
The major end user for thyroid cancer diagnosis are in Hospital Clinics, Cancer Diagnostic Centers and Research Institute. Geographically the global thyroid cancer diagnosis market is segmented into North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA).
Key players in global thyroid cancer diagnosis market are Merck KGaA, Abbott, F.Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Siemens Healthcare GmbH,Bio-Rad Laboratories, Inc., General Electric, Koninklijke Philips N.V., Toshiba Corporation, Agilent Technologies, Inc.,Illumina, Inc., GE Healthcare, Hologic, Inc., Medlife International Private Limited, Randox Laboratories Ltd, Tosoh India Pvt. Ltd., Quidel Corporation, American Cancer Society, Inc
Why to buy this report: